IP Library Granted Patent US 8,097,446
Granted Patent B2
US 8,097,446 · App. 12/398,821 · Granted Jan 17, 2012

Patent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,446
App. No.
12/398,821
Granted
Jan 17, 2012
Kind
B2
Abstract

This disclosure presents embodiments of novel strains of Staphylococcus aureus that through genetic engineering produce type 5 capsular polysaccharide at greater levels than Staphylococcus aureus strain Reynolds.

Claims (4)

1. An isolated deoxyribonucleic acid sequence comprising SEQ ID NO: 7.

2. A strain of Staphylococcus aureus comprising the isolated deoxyribonucleic acid sequence of claim 1 .

3. A strain of Staphylococcus aureus comprising an isolated DNA sequence comprising the cap1 promoter operably linked to the genes of the cap5 operon wherein the genes of the cap5 operon comprise the genes cap5A through cap5O as listed in SEQ ID NO: 7.

4. A strain of Staphylococcus aureus comprising an isolated DNA sequence, said DNA sequence comprising a constitutive promoter wherein said constitutive promoter is operably linked to a cap5 operon wherein said constitutive promoter is the cap1 promoter of Staphylococcus aureus strain M comprising SEQ ID NO: 2, and wherein the cap1 promoter and cap5 operon comprise the deoxyribonucleic acid sequence SEQ ID NO: 7.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2018
From: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 047667/0515 →